Author

A. Staebler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Hartkopf· 2 shared A. Koch· 2 shared C. Schmees· 2 shared K. Schenke-Layland· 2 shared N. Anderle· 2 shared A. C. Nelson· 1 shared A. Stahl· 1 shared A. Svedbom· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Hartkopf

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Clinical Significance of the Stromatic Component in Ovarian Cancer: Quantity Over Quality in Outcome Prediction

E. Lou, V. Clemente, M. Grube, A. Svedbom, A. C. Nelson, F. Blome, A. Staebler, S. Kommoss, M. Bazzaro

This study shows that higher tumor-stroma proportion (TSP) in ovarian cancer is linked to worse patient outcomes, including shorter progression-free and overall survival, and increased chemoresistance.

bioRxiv · Jun 27, 2023 · PreprintPathology

Protein profiling of breast carcinomas reveals expression of immune-suppressive factors and signatures relevant to patient outcome

F. Ruoff, N. Kersten, N. Anderle, S. Jerbi, A. Stahl, A. Koch, A. Staebler, A. Hartkopf, S. Y. Brucker, M. Hahn, K. Schenke-Layland, C. Schmees, M. Templin

The paper profiles proteins in breast carcinomas to identify immune-suppressive factors and signatures linked to patient outcomes.

bioRxiv · Jun 3, 2022Cancer Biology

A platform of patient-derived microtumors identifies therapeutic vulnerabilities in ovarian cancer.

N. Anderle, A. Koch, B. Gierke, A.-L. Keller, A. Staebler, A. Hartkopf, S. Brucker, M. Pawlak, K. Schenke-Layland, C. Schmees

This paper develops a 3D patient-derived microtumor platform to identify therapeutic vulnerabilities in ovarian cancer by testing drug responses and immune cell interactions.

bioRxiv · Nov 10, 2021 · PreprintCancer Biology